Statera Biopharma faces Nasdaq delisting as violations pile up
FORT COLLINS — Immunotherapy producer Statera Biopharma Inc. (Nasdaq: STAB) has until June 20 to produce a plan to get back within Nasdaq compliance. The troubled pharmaceutical company received a letter from the Nasdaq’s Listing Qualifications Department May 18 outlining the process it must undertake to comply with the Nasdaq’s listing rules.
The rule that the Nasdaq says Statera violated — Nasdaq Listing Rule 5250(C)(1) — orders companies listed with the Nasdaq to provide periodic reports on their financial situation. Statera missed the deadlines for its annual report for 2021 and its quarterly report for the period ending March…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Innosphere’s 2026 Life Sciences Incubator will feature a cohort of 38 startups from nine states…
-
PhotonPharma Inc., which specializes in tumor-specific immune therapies, received clearance this week from the U.S.…
-
FORT COLLINS — RedDrop Dx Inc., a Fort Collins-based client and portfolio company of Innosphere…
-
PhotonPharma Inc., which specializes in tumor-specific immune therapies, recently added William Warren to its board…
